v3.20.4
Intangible Assets and Goodwill
 12 Months Ended
Jan. 03, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Goodwill Intangible Assets and Goodwill
At the end of fiscal years 2020 and 2019, the gross and net amounts of intangible assets were:
(Dollars in Millions)20202019
Intangible assets with definite lives:  
Patents and trademarks — gross$39,990 36,634 
Less accumulated amortization17,618 13,154 
Patents and trademarks — net$22,372 23,480 
Customer relationships and other intangibles — gross$22,898 22,056 
Less accumulated amortization10,912 9,462 
Customer relationships and other intangibles — net*$11,986 12,594 
Intangible assets with indefinite lives:  
Trademarks$7,195 6,922 
Purchased in-process research and development(1)
11,849 4,647 
Total intangible assets with indefinite lives$19,044 11,569 
Total intangible assets — net$53,402 47,643 
*The majority is comprised of customer relationships
(1) In fiscal year 2020, the Company completed multiple acquisitions and recorded in-process research and development intangible assets of $6.0 billion from Momenta Pharmaceuticals, Inc., $0.8 billion for bermekimab and certain related assets from XBiotech, Inc., and $0.4 billion from the acquisition of all outstanding shares in Verb Surgical, Inc.


Goodwill as of January 3, 2021 and December 29, 2019, as allocated by segment of business, was as follows:
(Dollars in Millions)Consumer HealthPharmaceuticalMedical DevicesTotal
Goodwill at December 30, 2018$8,670 9,063 12,720 30,453 
Goodwill, related to acquisitions1,188 75 2,018 3,281 
Currency translation/other(122)31 (4)(95)
Goodwill at December 29, 2019$9,736 9,169 14,734 33,639 
Goodwill, related to acquisitions— 1,222 238 1,460 
Currency translation/other600 618 76 1,294 
Goodwill at January 3, 2021$10,336 11,009 15,048 36,393 


The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable assets included in cost of products sold was $4.7 billion, $4.5 billion and $4.4 billion before tax, for the fiscal years ended January 3, 2021, December 29, 2019 and December 30, 2018, respectively. Intangible asset write-downs are included in Other (income) expense, net.

The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:
(Dollars in Millions)
20212022202320242025
$4,6004,2004,1003,9003,200

See Note 18 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.